tetrodotoxin   

GtoPdb Ligand ID: 2616

Synonyms: TTX
Comment: Tetrodotoxin is a potent neurotoxin found in certain fish and other aquatic animals, although it is actually produced in symbiotic bacteria hosted in these creatures.
There is some ambiguity in the literature and on other databases as to the exact stereochemistry of tetrodotoxin. Our structure matches that on ChEBI and the PubChem entry linked to above, while the compound is also represented by the alternative isomer in CHEMBL507974 and CID 11174599.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tetrodotoxin

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 11
Hydrogen bond donors 8
Rotatable bonds 1
Topological polar surface area 190.25
Molecular weight 319.1
XLogP -3.58
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Canonical SMILES OCC1(O)C2OC3(OC1C1C(C2O)(C3O)NC(=NC1O)N)O
Isomeric SMILES OC[C@@]1(O)[C@H]2O[C@]3(O[C@@H]1[C@H]1[C@@]([C@H]2O)([C@@H]3O)NC(=N[C@@H]1O)N)O
InChI InChI=1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3+,4-,5+,6-,7+,9+,10-,11+/m1/s1
InChI Key CFMYXEVWODSLAX-QYIGHCJRSA-N
No information available.
Summary of Clinical Use
Subcutaneous tetrodotoxin has been evaluated in a Phase III clinical trial for its capacity to alleviate moderate to severe inadequately controlled cancer-related pain (NCT00725114).
Mechanism Of Action and Pharmacodynamic Effects
Mechanistically, tetrodotoxin blocks voltage-gated sodium channels to prevent the rising phase of the action potential. Tetrodotoxin poisoning causes loss of sensation, paralysis of voluntary muscles including the diaphragm and intercostal muscles which compromises respiration. Tetrodotoxin poisoning is serious but not always fatal.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00725114 Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain Phase 3 Interventional Wex Pharmaceuticals Inc.